Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.18 USD
−110.56 M USD
127.04 M USD
151.02 M
About Heron Therapeutics, Inc.
Sector
Industry
CEO
Craig A. Collard
Website
Headquarters
San Diego
Founded
1983
FIGI
BBG000G2GJT7
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
HRTX - Biotech long play Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Investment Snapshot (As o
$HRTX Inverse head and shouldersNot financial advice.
NASDAQ:HRTX possible inverse heads and shoulders. broke the downtrend line. will see if goes up to complete the neck.
Like and subscribe for more ideas.
Thanks.
HRTX a biotech penny stock with 70% in two months LONGHRTX has been suggested by various trading websites as a potentially explosive penny biotech
stock for 2024. It has experienced excellent price actions since an earnings beat in November.
It beat the estimates; that is to say it burned about half as much cash as the analysts estimated
the it wou
Liking this setup here, double bottom bullish divergenceWeekly timeframe RSI reminds me a Lot of Coinbase before it mega mooned.
In the context of the monthly timeframe, look where we are, all time lows. and bullish DIV on the MACD.
I don't know anything about this stock, just looking at the chart.
#HRTX $HRTX watching for continuation 👌nice trend with higher lows, is approaching resistance zone. a break of this can send it on parabolic move to upside.
short term targets are 3.7-3.86+
Potential rocket on 50-100%Heron Therapeutics, Inc - a biotech company whose main products are drugs for nausea and vomiting caused by chemotherapy (CINV), as well as painkillers. Capitalization of $1.2 billion. Located in San Diego, USA.
In May of this year, the company received FDA approval for its "breakthrough" pain medi
HRTX - Areas of interestThere are very clearly visible daily order blocks on both side of the price. Wait for price to come to those zones and then look for rejection on a smaller time frame - then trade along.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of HRTX is 1.58 USD — it has increased by 3.27% in the past 24 hours. Watch Heron Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Heron Therapeutics, Inc. stocks are traded under the ticker HRTX.
HRTX stock has fallen by −3.07% compared to the previous week, the month change is a 32.22% rise, over the last year Heron Therapeutics, Inc. has showed a −4.24% decrease.
We've gathered analysts' opinions on Heron Therapeutics, Inc. future price: according to them, HRTX price has a max estimate of 9.00 USD and a min estimate of 4.00 USD. Watch HRTX chart and read a more detailed Heron Therapeutics, Inc. stock forecast: see what analysts think of Heron Therapeutics, Inc. and suggest that you do with its stocks.
HRTX reached its all-time high on Jan 13, 1992 with the price of 1,290.00 USD, and its all-time low was 0.50 USD and was reached on Nov 9, 2023. View more price dynamics on HRTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
HRTX stock is 10.96% volatile and has beta coefficient of 1.02. Track Heron Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Heron Therapeutics, Inc. there?
Today Heron Therapeutics, Inc. has the market capitalization of 240.31 M, it has decreased by −2.37% over the last week.
Yes, you can track Heron Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Heron Therapeutics, Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
HRTX earnings for the last quarter are −0.03 USD per share, whereas the estimation was −0.04 USD resulting in a 20.79% surprise. The estimated earnings for the next quarter are −0.03 USD per share. See more details about Heron Therapeutics, Inc. earnings.
Heron Therapeutics, Inc. revenue for the last quarter amounts to 32.81 M USD, despite the estimated figure of 36.77 M USD. In the next quarter, revenue is expected to reach 37.29 M USD.
HRTX net income for the last quarter is −4.85 M USD, while the quarter before that showed −9.23 M USD of net income which accounts for 47.50% change. Track more Heron Therapeutics, Inc. financial stats to get the full picture.
No, HRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 126.00 employees. See our rating of the largest employees — is Heron Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Heron Therapeutics, Inc. EBITDA is −23.30 M USD, and current EBITDA margin is −84.79%. See more stats in Heron Therapeutics, Inc. financial statements.
Like other stocks, HRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Heron Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Heron Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Heron Therapeutics, Inc. stock shows the sell signal. See more of Heron Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.